Biofourmis vs Tortus
A detailed comparison to help you choose between Biofourmis and Tortus.
🏆
Verdict: Tortus wins
Tortus scores 4.3/5, edging out Biofourmis at 3.6/5. NHS trusts and ICSs procuring an ambient clinical scribe with regulatory coverage, published safety data, and direct EHR write-back — especially those on Epic, Oracle Health, EMIS or SystmOne.
Biofourmis AI-powered patient monitoring and clinical insights for chronic disease management | Tortus AI-powered healthcare efficiency and EHR optimization | |
|---|---|---|
| Rating | 3.6 (1 review) | 4.3 (1 review) |
| Pricing Model | paid | paid |
| Starting Price | From $1000/mo | From $99/mo |
| Best For | Large health systems, IDNs and payers standing up hospital-at-home, post-acute or chronic-care monitoring programmes at scale who want FDA-cleared predictive analytics bundled with the clinical teams to act on it. | NHS trusts and ICSs procuring an ambient clinical scribe with regulatory coverage, published safety data, and direct EHR write-back — especially those on Epic, Oracle Health, EMIS or SystmOne. |
| Free Tier | ||
| API Access | ||
| Team Features | ||
| Open Source | ||
| Tags | ssoteam features | team featuresgdpr compliantapi access |
| Visit Biofourmis → | Visit Tortus → |
Biofourmis
Pros
- + FDA-cleared analytics with Breakthrough Device Designation for BiovitalsHF — the strongest regulatory validation I have found in the RPM category.
- + The Biovitals engine models each patient against their own physiological baseline instead of population norms, which should meaningfully cut alert noise compared with threshold-based RPM (worth testing in any pilot).
- + It sells the escalation pathway with the software: virtual nursing, licensed navigators and in-home services (diagnostics, DME, meds, transport) orchestrated in one clinician dashboard — addressing the 2am-response gap that sinks most monitoring programmes.
- + Proven health-system deployments — AdventHealth acute care-at-home (January 2025), Lee Health hospital-at-home expansion (November 2024), plus UCI Health, Orlando Health, Augusta University Health and others named in company materials.
- + Device-agnostic sensor strategy with Epic EHR integration and a GE HealthCare partnership extending monitoring from hospital to home, so it fits existing clinical infrastructure rather than replacing it.
Cons
- - Zero commercial transparency: enterprise-only, no public pricing, custom contracts priced on patient volume and programme type — there is nothing to anchor a negotiation against.
- - The company has been through 120 layoffs (July 2023), a founder-CEO departure, an all-stock merger with CopilotIQ (October 2024) and a divestiture of its life-sciences arm (January 2025) — continuity risk on multi-year contracts.
- - Key performance claims (120+ biomarkers, deterioration detected days ahead, readmission reduction) are vendor-reported; I could not find independent head-to-head clinical evaluations.
- - No longer a clinical-trials vendor: biopharma buyers must now go to ActiGraph, which acquired Biofourmis Connect in January 2025.
- - It is a service-plus-software purchase — clinical staffing is embedded in the model, so the labour agreement carries as much delivery risk as the platform itself.
Tortus
Pros
- + Published safety evidence: hallucination-check layer verified against the transcript with a 75% reduction in major hallucinations reported in npj Digital Medicine — rare transparency in this category
- + Direct Epic and Oracle Health integration with context-aware launch from the patient chart and signed notes written back to the EHR, not copy-paste exports
- + UKCA Class IIa medical device with ISO 13485, ISO 27001, Cyber Essentials Plus, DTAC and DSPT — the most regulatory coverage I found among UK scribes
- + Third-party evaluated outcomes: documentation time halved and 47 minutes back per shift at St George's (GOSH DRIVE for NHS England); 15,000 more appointments/year projected at Royal Devon
- + Published G-Cloud pricing (enterprise £200,000/year incl. 100,000 audio hours, £44/licence/month small pilot) lets procurement model cost before a sales call
Cons
- - No self-serve path for small clinics — everything routes through NHS trust procurement or the X-on Health partnership; smallest pilot caps at 20 licences and 1-2 departments
- - G-Cloud pricing documents carry conflicting validity dates (offers valid to 31/03/2025 vs G-Cloud 15 live from 7 Sept) — current figures need confirming in procurement
- - Template customisation is more limited than some competitors despite per-specialty templates
- - UK-centric: built around NHS governance and UK record systems with no documented private-practice PMS integration
- - Clinical performance claims rest on published evaluations and vendor documentation — there is no way for an individual reviewer to test the device in a real consultation
Frequently Asked Questions
Which is better, Biofourmis or Tortus?▼
Tortus scores higher at 4.3/5 vs 3.6/5 for Biofourmis, making it the better-rated option in our comparison.
What is the difference between Biofourmis and Tortus?▼
Biofourmis: Biofourmis runs remote patient monitoring and care-at-home programmes, combining wearable data with clinical analytics for health systems and life-science companies. Tortus: TORTUS is a clinical AI assistant used in NHS systems that writes consultation notes automatically while the clinician talks to the patient.
Is Biofourmis or Tortus more affordable?▼
Biofourmis starts at €1000/mo, Tortus starts at €99/mo. Check the comparison table above for current pricing.
Stay in the loop
Get weekly updates on the best new AI tools, deals, and comparisons.
No spam. Unsubscribe anytime.